Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Solventum Stock Outperforming the Nasdaq?

Valued at a market cap of $14.4 billion, Solventum Corporation (SOLV) is a Minnesota-based healthcare company, focused on delivering medical and health technology solutions. The company operates in medical-surgical products, dental solutions, health information systems, and purification and filtration technologies, serving hospitals, dental practices, and healthcare providers globally. 

Companies worth $10 billion or more are typically classified as “large-cap stocks,” and SOLV fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the medical instruments & supplies industry. Solventum aims to leverage its strong legacy brands, innovation capabilities, and global distribution network to...

Fundamentals

See More
  • Market Capitalization, $K 57,109,488
  • Shares Outstanding, K 285,419
  • Annual Sales, $ 21,840 M
  • Annual Income, $ 1,678 M
  • EBIT $ 2,578 M
  • EBITDA $ 5,040 M
  • 60-Month Beta 0.25
  • Price/Sales 2.63
  • Price/Cash Flow 8.70
  • Price/Book 2.27

Options Overview Details

View History
  • Implied Volatility 22.04% (-1.31%)
  • Historical Volatility 24.87%
  • IV Percentile 32%
  • IV Rank 22.09%
  • IV High 40.49% on 04/10/25
  • IV Low 16.81% on 02/11/25
  • Expected Move (DTE 3) 4.12 (2.09%)
  • Put/Call Vol Ratio 1.04
  • Today's Volume 149
  • Volume Avg (30-Day) 1,380
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 30,580
  • Open Int (30-Day) 22,104
  • Expected Range 193.06 to 201.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.82
  • Number of Estimates 7
  • High Estimate 2.85
  • Low Estimate 2.79
  • Prior Year 3.43
  • Growth Rate Est. (year over year) -17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
188.04 +4.69%
on 11/20/25
202.75 -2.91%
on 12/12/25
+3.82 (+1.98%)
since 11/14/25
3-Month
162.29 +21.30%
on 11/06/25
202.75 -2.91%
on 12/12/25
+10.65 (+5.72%)
since 09/16/25
52-Week
162.29 +21.30%
on 11/06/25
251.99 -21.88%
on 02/03/25
-30.70 (-13.49%)
since 12/16/24

Most Recent Stories

More News
Is Solventum Stock Outperforming the Nasdaq?

Solventum has delivered stronger performance than the Nasdaq Composite over the past year, reinforcing analysts’ moderate optimism regarding the stock’s forward outlook.

SOLV : 81.03 (-1.05%)
$NASX : 23,015.75 (-0.18%)
BDX : 197.12 (-1.48%)
BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec

FRANKLIN LAKES, N.J. , Dec. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of its respiratory...

BDX : 197.12 (-1.48%)
Baxter International Stock: Is BAX Underperforming the Health Care Sector?

Baxter International has lagged the broader health care sector by a wide margin over the past year, and analysts are taking a guarded stance on its outlook.

XLV : 153.78 (-1.49%)
BDX : 197.12 (-1.48%)
BAX : 19.14 (-2.00%)
3 Reasons BDX is Risky and 1 Stock to Buy Instead

3 Reasons BDX is Risky and 1 Stock to Buy Instead

BDX : 197.12 (-1.48%)
BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories

FRANKLIN LAKES, N.J. , Dec. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ChemoGLO™, a specialist in hazardous drug detection...

BDX : 197.12 (-1.48%)
BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes

Three- and Four-Laser BD FACSDiscover™ A8 Cell Analyzers Expand Accessibility of Spectral, Real-Time Imaging Cell Analysis

BDX : 197.12 (-1.48%)
Is Becton, Dickinson and Company Stock Underperforming the Nasdaq?

Becton, Dickinson and Company has notably underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

SOLV : 81.03 (-1.05%)
$NASX : 23,015.75 (-0.18%)
BDX : 197.12 (-1.48%)
BD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety

FRANKLIN LAKES, N.J. , Nov. 24, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Surgiphor™...

BDX : 197.12 (-1.48%)
1 Profitable Stock to Own for Decades and 2 We Avoid

1 Profitable Stock to Own for Decades and 2 We Avoid

PRIM : 129.77 (-0.60%)
BDX : 197.12 (-1.48%)
MAIN : 60.53 (-0.39%)
3 Healthcare Stocks We Approach with Caution

3 Healthcare Stocks We Approach with Caution

PACB : 2.04 (-3.77%)
BDX : 197.12 (-1.48%)
BRKR : 44.69 (-2.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational...

See More

Key Turning Points

3rd Resistance Point 206.11
2nd Resistance Point 204.28
1st Resistance Point 202.18
Last Price 197.12
1st Support Level 198.25
2nd Support Level 196.42
3rd Support Level 194.32

See More

52-Week High 251.99
Fibonacci 61.8% 217.72
Fibonacci 50% 207.14
Last Price 197.12
Fibonacci 38.2% 196.55
52-Week Low 162.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar